Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Ephedra Evidence Report Targeted For August 2002 Release

This article was originally published in The Tan Sheet

Executive Summary

An Agency for Healthcare Research & Quality report on the safety and efficacy of ephedra, commissioned by the National Institutes of Health, could be released as early as August 2002.
Advertisement

Related Content

RAND Report Recommends Case-Control Ephedra Study Look At AE Risk
Ephedra OTC Drug Status Consideration Floated By AHPA’s McGuffin
SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ
Metabolife Proposes NIH “Blue Ribbon” Commission To Complement RAND
NTP Ephedrine Alkaloid Toxicity Studies Under Review
USP Ephedra Review Scheduled For July; RAND Report Slated For Early Fall
ODS Evidence-Based Review Program Recruits NCI Official
Private CAM Research Incentives Advocated By White House Commission
Labor/HHS
Multi-Ingredient Supplements Warrant Priority Safety Review - Whitehall Rep

Topics

Advertisement
UsernamePublicRestriction

Register

PS092894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel